from ceoFrom the desk of our CEO, George W. Evans, JD, MBA

 

In my last letter I talked about changing directions. It's not unexpected in our business and is often a natural result of learning more about our products--that's what gets us up in the morning. Our recent progress has been a bit more linear, though, and we've found with Kevetrin(TM) that the more we learn, the more interesting it gets.

Over the past few months, we've done both in vitro and in vivo studies as we prepare for our IND filing with the U.S. FDA. With each study we've become more encouraged about the prospects for Kevetrin. We've found that the first results in drug resistant lung cancer cell lines weren't a fluke--in fact we've found consistently good activity in drug resistant breast cancer cell lines, as well. And we've started to learn that Kevetrin is pretty selective in the way it impacts anti-tumor pathways. It's not primarily a cytotoxic compound, with all the baggage that can bring.

Full Letter....

 

Latest NewsNewsletters
 

Latest NewsLatest News

 
10.20.2009


Cellceutix Announces Acquisition of New Compound
10.19.2009


Startup pharma company runs a tight ship on path to crucial human testing
10.06.2009

Interview with George Evans, Cellceutix's CEO, at SmallCapVoice.com

Latest NewsPress Releases

 
11.02.2009
Cellceutix Signs Agreement for Kevetrin(TM) Safety Studies with Toxikon Corporation 10.20.2009
Attacking Cancer with Specific Anti-Tumor Pathways 10.13.2009
Dr. Menon Selected For Expert Panel